Xigen Raises $20 Million
Xigen, a Swiss developer of therapeutic peptides, has raised $20 million in Series B funding from return backer Tilocor Life Science.
20 November 2009•4 mins read
Xigen, a Swiss developer of therapeutic peptides, has raised $20 million in Series B funding from return backer Tilocor Life Science.
